Cargando…

Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Uemura, Motohide, Nakaigawa, Noboru, Sassa, Naoto, Tatsugami, Katsunori, Harada, Kenichi, Yamasaki, Toshinari, Matsubara, Nobuaki, Yoshimoto, Takuya, Nakagawa, Yuki, Fukuyama, Tamaki, Oya, Mototsugu, Shinohara, Nobuo, Uemura, Hirotsugu, Tsuzuki, Toyonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523015/ https://www.ncbi.nlm.nih.gov/pubmed/34449010 http://dx.doi.org/10.1007/s10147-021-02008-5

Ejemplares similares

Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
por: Nakaigawa, Noboru, et al.
Publicado: (2023)

Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients
por: Tomita, Yoshihiko, et al.
Publicado: (2020)

The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis
por: Fujita, Kazutoshi, et al.
Publicado: (2022)

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2016)

Sarcomatoid Variant of Bladder Carcinoma: A Case Report
por: Uemura, Koichi, et al.
Publicado: (2018)

A case of renal cell carcinoma with microscopic pulmonary tumor embolism proven by surgical lung biopsy
por: Katano, Takuma, et al.
Publicado: (2022)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
por: Hinata, Nobuyuki, et al.
Publicado: (2020)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2023)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
por: Kosaka, Takeo, et al.
Publicado: (2019)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Guo, Jun, et al.
Publicado: (2018)

Renal Cell Carcinoma in a Horseshoe Kidney Treated with Laparoscopic Partial Nephrectomy
por: Ohtake, Shinji, et al.
Publicado: (2018)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system
por: Harashima, Nanae, et al.
Publicado: (2014)

Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study
por: Tamada, Satoshi, et al.
Publicado: (2022)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
por: Eto, Masatoshi, et al.
Publicado: (2015)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
por: Shinohara, Nobuo, et al.
Publicado: (2015)

Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
por: Takahashi, Shunji, et al.
Publicado: (2018)

Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy
por: Kawahara, Takashi, et al.
Publicado: (2019)

Spontaneous adrenal hemorrhage with dehydroepiandrosterone‐sulfate elevation in a patient with suspected adrenal cortical carcinoma
por: Shimokihara, Kota, et al.
Publicado: (2019)

The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer
por: Tatenuma, Tomoyuki, et al.
Publicado: (2019)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
por: Eto, Masatoshi, et al.
Publicado: (2014)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2013)

A safe combined nephrectomy and right lobectomy using the liver hanging maneuver for huge renal cell carcinoma directly invading the right lobe of the liver: report of a case
por: Yoshimatsu, Masanori, et al.
Publicado: (2013)

From Molecule to Patient: Building Bridges Not Walls with Clinical Pharmacology and Translational Medicine
por: Uemura, Naoto
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4hilfknghgkachlkc1u21ht33u